<p>2025 年 10 月 10 日- 上午 08:37</p>
<p>台湾台北，2025 年 10 月 10 日（GLOBE NEWSWIRE）-- YD Bio Limited（“YD Bio” 或 “公司”）（纳斯达克：YDES），一家推进基于 DNA 甲基化的癌症检测技术和眼科创新的生物技术公司，今天宣布其商业合作伙伴 EG Biomed US Inc.（“EG BioMed”），是公司在胰腺癌和乳腺癌检测方面的许可合作伙伴之一，并与 3D Global 合作开发眼部疾病治疗，已获得美国病理学家学院（CAP）实验室认证项目的认证，认证其位于华盛顿州博塞尔的 CLIA 认证实验室（CLIA 证书#50D2316600）。</p>
<p>CAP 认证被广泛认为是实验室质量保证的黄金标准，确认 EG BioMed 符合实验室运营的最高卓越标准。结合其现有的 CLIA 认证，这一认可进一步增强了 EG BioMed 在美国市场支持 YD Bio 癌症检测项目和诊断创新方面提供先进实验室开发测试（LDTs）的能力。</p>
<p>“我们非常高兴看到我们的合作伙伴 EG BioMed 获得这一声望卓著的认可，” YD Bio Limited 创始人、董事长兼首席执行官 Ethan Shen 博士表示。“CAP 认证强调了我们通过科学创新和精准医疗改善患者结果的承诺，并增强了我们为患者提供准确、可靠诊断的能力，进一步确立了我们作为精准诊断领域可信赖领导者的地位。这一成就代表了我们实现提供创新解决方案以提升生活质量和拯救生命使命的重要一步。”</p>
<p>随着 CAP 认证的获得，YD Bio 和 EG BioMed 在扩展其诊断产品组合方面处于良好位置，专注于早期癌症检测和监测。结合 YD Bio 的眼科产品和其他突破性医疗解决方案，公司继续推进改善患者结果和生活质量的使命。</p>
<p>进一步强调 EG BioMed 的科学领导力，EG BioMed 首席研发官、台北医学大学教授林若凯在 2025 年 9 月 28 日至 10 月 1 日在波士顿举行的美国癌症研究协会（AACR）胰腺癌研究进展特别会议上展示了新发现。她的演讲强调了一种新型循环游离 DNA 生物标志物，具有监测晚期胰腺癌转移和疾病进展的潜力。</p>
<p><strong>关于 YD Bio Limited</strong></p>
<p>YD Bio Limited 是一家生物技术公司，专注于推进临床试验、新药开发、癌症预防诊断以及具有转变高未满足医疗需求疾病治疗潜力的干细胞和外泌体疗法。公司致力于通过科学创新和精准医疗改善患者结果。除了研发工作，YD Bio Limited 还是临床试验药物的公认供应商，并已扩展到后市场辅助产品的开发和分销。有关更多信息，请访问公司网站：ir.ydesgroup.com</p>
<p><strong><em>前瞻性声明</em></strong></p>
<p><em>本公告中的某些声明是前瞻性声明，包括但不限于 YD Bio 的商业计划和前景。这些前瞻性声明涉及已知和未知的风险和不确定性，并基于 YD Bio 对未来事件的当前预期和预测，YD Bio 认为这些事件可能影响其财务状况、经营结果、商业战略和财务需求。投资者可以通过 “近似”、“相信”、“希望”、“期待”、“预期”、“估计”、“项目”、“打算”、“计划”、“将”、“会”、“应该”、“可能”、“或其他类似表达” 来识别这些前瞻性声明。YD Bio 没有义务公开更新或修订任何前瞻性声明，以反映后续发生的事件或情况，或其预期的变化，除非法律要求。尽管 YD Bio 相信这些前瞻性声明中表达的预期是合理的，但不能保证这些预期会被证明是正确的，YD Bio 提醒投资者实际结果可能与预期结果有重大差异，并鼓励投资者查看可能影响其未来结果的其他因素，这些因素在 YD Bio 的注册声明和其他向美国证券交易委员会的文件中有所说明。</em></p>
<p><strong>如需投资者和媒体咨询，请联系：</strong></p>
<p>YD Bio Limited</p>
<p>投资者关系</p>
<p>电子邮件：investor@ydesgroup.com</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.globenewswire.com/newsroom/ti/query-bmY9T1RVME16WXhNeU0zTVRrd01EVTJJelV3TURFMU16SXdNZz09?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.globenewswire.com/newsroom/ti/query-bmY9T1RVME16WXhNeU0zTVRrd01EVTJJelV3TURFMU16SXdNZz09"/></p>
<p><img src="https://imageproxy.pbkrs.com/https://ml.globenewswire.com/media/NGNmMzY5MmMtOTI4Yy00NDRlLTk2YzItMDQxOTQ3NWIwNWQxLTUwMDE1MzIwMi0yMDI1LTEwLTEwLWVu/tiny/YD-Bio-Limited.png?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://ml.globenewswire.com/media/NGNmMzY5MmMtOTI4Yy00NDRlLTk2YzItMDQxOTQ3NWIwNWQxLTUwMDE1MzIwMi0yMDI1LTEwLTEwLWVu/tiny/YD-Bio-Limited.png"/></p>

YDES

<p>YD Bio Limited 的合作伙伴 EG Biomed US Inc. 在华盛顿州博塞尔的实验室获得了 CAP 认证，增强了其在癌症检测方面的能力。该认证被视为实验室质量的黄金标准，支持 YD Bio 通过创新诊断改善患者结果的使命。YD Bio 的首席执行官沈以恒博士强调了这一成就对提供可靠诊断的重要性。此外，EG Biomed 在最近的一次会议上展示了用于监测晚期胰腺癌的生物标志物的新研究，进一步巩固了其科学领导地位</p>

<p>10/10/2025 - 08:37 AM</p>
<div class="lb-trans"><p>2025 年 10 月 10 日- 上午 08:37</p>
</div><p>Taipei, Taiwan, Oct. 10, 2025 (GLOBE NEWSWIRE) -- YD Bio Limited (“YD Bio” or the “Company”) (Nasdaq: YDES), a biotechnology company advancing DNA methylation-based cancer detection technology and ophthalmologic innovations, today announced that its business partner, EG Biomed US Inc. (“EG BioMed”) one of the Company’s licensing partners for pancreatic and breast cancer detection and with 3D Global to develop treatment for eye disorders, has been accredited by the College of American Pathologists’ (CAP) Laboratory Accreditation Program for its CLIA-certified laboratory in Bothell, Washington (CLIA Certificate #50D2316600).</p>
<div class="lb-trans"><p>台湾台北，2025 年 10 月 10 日（GLOBE NEWSWIRE）-- YD Bio Limited（“YD Bio” 或 “公司”）（纳斯达克：YDES），一家推进基于 DNA 甲基化的癌症检测技术和眼科创新的生物技术公司，今天宣布其商业合作伙伴 EG Biomed US Inc.（“EG BioMed”），是公司在胰腺癌和乳腺癌检测方面的许可合作伙伴之一，并与 3D Global 合作开发眼部疾病治疗，已获得美国病理学家学院（CAP）实验室认证项目的认证，认证其位于华盛顿州博塞尔的 CLIA 认证实验室（CLIA 证书#50D2316600）。</p>
</div><p>CAP accreditation, widely recognized as the gold standard in laboratory quality assurance, confirms that EG BioMed meets the highest standards of excellence in laboratory operations. Together with its existing CLIA certification, this recognition further strengthens EG BioMed’s ability to deliver advanced laboratory-developed tests (LDTs) in support of YD Bio’s cancer detection programs and diagnostic innovations in the U.S. market.</p>
<div class="lb-trans"><p>CAP 认证被广泛认为是实验室质量保证的黄金标准，确认 EG BioMed 符合实验室运营的最高卓越标准。结合其现有的 CLIA 认证，这一认可进一步增强了 EG BioMed 在美国市场支持 YD Bio 癌症检测项目和诊断创新方面提供先进实验室开发测试（LDTs）的能力。</p>
</div><p>“We are thrilled to see our partner company, EG BioMed, achieve this prestigious recognition,” said Dr. Ethan Shen, Founder, Chairman and Chief Executive Officer of YD Bio Limited. “CAP accreditation underscores our commitment to improving patient outcomes through scientific innovation and precision, and it strengthens our ability to deliver accurate, reliable diagnostics to patients, and further establishes us as a trusted leader in precision diagnostics. This achievement represents an important step toward our mission of delivering innovative solutions that enhance quality of life and save lives.”</p>
<div class="lb-trans"><p>“我们非常高兴看到我们的合作伙伴 EG BioMed 获得这一声望卓著的认可，” YD Bio Limited 创始人、董事长兼首席执行官 Ethan Shen 博士表示。“CAP 认证强调了我们通过科学创新和精准医疗改善患者结果的承诺，并增强了我们为患者提供准确、可靠诊断的能力，进一步确立了我们作为精准诊断领域可信赖领导者的地位。这一成就代表了我们实现提供创新解决方案以提升生活质量和拯救生命使命的重要一步。”</p>
</div><p>With CAP accreditation secured, YD Bio and EG BioMed are well positioned to expand their diagnostic portfolio, focusing on early cancer detection and monitoring. Along with YD Bio’s ophthalmology products and other breakthrough healthcare solutions, the Company continues to advance its mission to improve patient outcomes and quality of life.</p>
<div class="lb-trans"><p>随着 CAP 认证的获得，YD Bio 和 EG BioMed 在扩展其诊断产品组合方面处于良好位置，专注于早期癌症检测和监测。结合 YD Bio 的眼科产品和其他突破性医疗解决方案，公司继续推进改善患者结果和生活质量的使命。</p>
</div><p>Further underscoring ED BioMed’s scientific leadership, Ruo-Kai Lin, Chief R&amp;D Officer of EG BioMed and Professor of Taipei Medical University, presented new findings at the American Association for Cancer Research (AACR) special Conference on Advances in Pancreatic Cancer Research, held in Boston from September 28 to October 1, 2025. Her presentation highlighted a novel circulating cell-free DNA biomarker with potential to monitor metastasis and disease progression in advanced pancreatic cancer.</p>
<div class="lb-trans"><p>进一步强调 EG BioMed 的科学领导力，EG BioMed 首席研发官、台北医学大学教授林若凯在 2025 年 9 月 28 日至 10 月 1 日在波士顿举行的美国癌症研究协会（AACR）胰腺癌研究进展特别会议上展示了新发现。她的演讲强调了一种新型循环游离 DNA 生物标志物，具有监测晚期胰腺癌转移和疾病进展的潜力。</p>
</div><p><strong>About YD Bio Limited</strong></p>
<div class="lb-trans"><p><strong>关于 YD Bio Limited</strong></p>
</div><p>YD Bio Limited is a biotechnology company focused on advancing clinical trials, new drug development, cancer prevention diagnostics, and stem cell and exosome therapies with the potential to transform the treatment of diseases with high unmet medical need. The Company is committed to improving patient outcomes through scientific innovation and precision medicine. In addition to its R&amp;D efforts, YD Bio Limited is a recognized supplier of clinical trial drugs and has expanded into the development and distribution of post-market auxiliary products. For more information, please visit the Company’s website: ir.ydesgroup.com</p>
<div class="lb-trans"><p>YD Bio Limited 是一家生物技术公司，专注于推进临床试验、新药开发、癌症预防诊断以及具有转变高未满足医疗需求疾病治疗潜力的干细胞和外泌体疗法。公司致力于通过科学创新和精准医疗改善患者结果。除了研发工作，YD Bio Limited 还是临床试验药物的公认供应商，并已扩展到后市场辅助产品的开发和分销。有关更多信息，请访问公司网站：ir.ydesgroup.com</p>
</div><p><strong><em>Forward-Looking Statements</em></strong></p>
<div class="lb-trans"><p><strong><em>前瞻性声明</em></strong></p>
</div><p><em>Certain statements in this announcement are forward-looking statements, including, but not limited to, YD Bio’s business plan and outlook. These forward-looking statements involve known and unknown risks and uncertainties and are based on YD Bio’s current expectations and projections about future events that YD Bio believes may affect its financial condition, results of operations, business strategy and financial needs. Investors can identify these forward-looking statements by words or phrases such as “approximates,” “believes,” “hopes,” “expects,” “anticipates,” “estimates,” “projects,” “intends,” “plans,” “will,” “would,” “should,” “could,” “may” or other similar expressions. YD Bio undertakes no obligation to update or revise publicly any forward-looking statements to reflect subsequent occurring events or circumstances, or changes in its expectations, except as may be required by law. Although YD Bio believes that the expectations expressed in these forward-looking statements are reasonable, it cannot assure you that such expectations will turn out to be correct, and YD Bio cautions investors that actual results may differ materially from the anticipated results and encourages investors to review other factors that may affect its future results in YD Bio’s registration statement and other filings with the U.S. Securities and Exchange Commission.</em></p>
<div class="lb-trans"><p><em>本公告中的某些声明是前瞻性声明，包括但不限于 YD Bio 的商业计划和前景。这些前瞻性声明涉及已知和未知的风险和不确定性，并基于 YD Bio 对未来事件的当前预期和预测，YD Bio 认为这些事件可能影响其财务状况、经营结果、商业战略和财务需求。投资者可以通过 “近似”、“相信”、“希望”、“期待”、“预期”、“估计”、“项目”、“打算”、“计划”、“将”、“会”、“应该”、“可能”、“或其他类似表达” 来识别这些前瞻性声明。YD Bio 没有义务公开更新或修订任何前瞻性声明，以反映后续发生的事件或情况，或其预期的变化，除非法律要求。尽管 YD Bio 相信这些前瞻性声明中表达的预期是合理的，但不能保证这些预期会被证明是正确的，YD Bio 提醒投资者实际结果可能与预期结果有重大差异，并鼓励投资者查看可能影响其未来结果的其他因素，这些因素在 YD Bio 的注册声明和其他向美国证券交易委员会的文件中有所说明。</em></p>
</div><p><strong>For investor and media inquiries, please contact:</strong></p>
<div class="lb-trans"><p><strong>如需投资者和媒体咨询，请联系：</strong></p>
</div><p>YD Bio Limited</p>
<div class="lb-trans"><p>YD Bio Limited</p>
</div><p>Investor Relations</p>
<div class="lb-trans"><p>投资者关系</p>
</div><p>Email: investor@ydesgroup.com</p>
<div class="lb-trans"><p>电子邮件：investor@ydesgroup.com</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.globenewswire.com/newsroom/ti/query-bmY9T1RVME16WXhNeU0zTVRrd01EVTJJelV3TURFMU16SXdNZz09" alt="" original-src="https://www.globenewswire.com/newsroom/ti?nf=OTU0MzYxMyM3MTkwMDU2IzUwMDE1MzIwMg=="/></p>
<p><img src="https://imageproxy.pbkrs.com/https://ml.globenewswire.com/media/NGNmMzY5MmMtOTI4Yy00NDRlLTk2YzItMDQxOTQ3NWIwNWQxLTUwMDE1MzIwMi0yMDI1LTEwLTEwLWVu/tiny/YD-Bio-Limited.png" alt="" original-src="https://ml.globenewswire.com/media/NGNmMzY5MmMtOTI4Yy00NDRlLTk2YzItMDQxOTQ3NWIwNWQxLTUwMDE1MzIwMi0yMDI1LTEwLTEwLWVu/tiny/YD-Bio-Limited.png"/></p>

YD Bio 的业务合作伙伴 EG Biomed 获得了 CAP 认证，提升了其在美国的临床检测能力 | YDES 股票新闻